An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

Vascular Medicine (United Kingdom)

Volumn 20, Issue 5, 2015, Pages 465-478

  Jaff, Michael R ^a   White, Christopher J ^b   Hiatt, William R ^c   Fowkes, Gerry R ^d   Dormandy, John ^e   Razavi, Mahmood ^f   Reekers, Jim ^g   Norgren, Lars ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f ST JOSEPH HOSPITAL   (United States)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

angioplasty; arteries; claudication; critical limb ischemia; occlusion; peripheral artery disease; revascularization; stenosis; stents; surgery

Indexed keywords

POLITEF;

ABDOMINAL AORTA ANEURYSM; ARTERY OCCLUSION; ARTICLE; ATHERECTOMY; BALLOON; BARE METAL STENT; BARE NITINOL STENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ELUTING BALLOON; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; EVEROLIMUS ELUTING CORONARY STENT; FABRIC COVERED NITINOL STENT; FEMOROPOPLITEAL BYPASS; FEMOROPOPLITEAL DISEASE; HUMAN; ILIAC ARTERY OBSTRUCTION; INFRAPOPLITEAL DISEASE; KINESIOTHERAPY; LENGTH OF STAY; LERICHE SYNDROME; MATERIAL COATING; MORTALITY; NITINOL STENT; OUTCOME ASSESSMENT; PACLITAXEL-ELUTING BALLOON; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; SELF EXPANDING STENT; SIROLIMUS ELUTING CORONARY STENT; SUPERFICIAL FEMORAL ARTERY OCCLUSION; SURGICAL APPROACH; THORACIC AORTA ANEURYSM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORK EXPERIENCE; ISCHEMIA; LOWER LIMB; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; VASCULARIZATION;

ENDOVASCULAR PROCEDURES; HUMANS; ISCHEMIA; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; TREATMENT OUTCOME;

EID: 84943160199     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X15597877     Document Type: Article

References (90)

1. Dormandy JA, Rutherford RB,. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31: S1-S296.
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S: S5-67.
3. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007; 116: 285-292.
4. Saxon RR, Dake MD, Volgelzang RL, et al. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008; 19: 823-832.
5. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008; 118: 1358-1365.
6. Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009; 50: 54-60.
7. Diehm N, Schillinger M, Minar E, et al. TASC II section E3 on the treatment of acute limb ischemia: commentary from European interventionists. J Endovasc Ther. 2008; 15: 126-128.
8. Schillinger M, Diehm N, Baumgartner I, et al. TASC II section F on revascularization: commentary from an interventionists point of view. J Endovasc Ther. 2007; 14: 734-742.
9. Indes JE, Mandawat A, Tuggle CT, et al. Endovascular procedures for aorto-iliac occlusive disease are associated with superior short-term clinical and economic outcomes compared with open surgery in the inpatient population. J Vasc Surg. 2010; 52: 1173-1179.
10. Indes JE, Pfaff MJ, Farrokhyar F, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. J Endovasc Ther. 2013; 20: 443-455.
11. Leville CD, Kashyap VS, Clair DG, et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J Vasc Surg. 2006; 43: 32-39.
12. Hans SS, DeSantis D, Siddiqui R, et al. Results of endovascular therapy and aortobifemoral grafting for Transatlantic Inter-Society type C and D aortoiliac occlusive disease. Surgery. 2008; 144: 583-590.
13. Jongkind V, Akkersdijk GJ, Yeung KK, et al. A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg. 2010; 52: 1376-1383.
14. Ye W, Liu CW, Ricco JB, et al. Early and late outcomes of percutaneous treatment of TransAtlantic Inter-Society Consensus class C and D aorto-iliac lesions. J Vasc Surg. 2011; 53: 1728-1737.
15. Clair DG, Adams J, Reen B, et al. The EPIC nitinol stent system in the treatment of iliac artery lesions: one-year results from the ORION clinical trial. J Endovasc Ther. 2014; 21: 213-222.
16. Mwipatayi BP, Thomas S, Wong J, et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011; 54: 1561-1570.
17. Sabri SS, Choudhri A, Orgera G, et al. Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. J Vasc Interv Radiol. 2010; 21: 995-1003.
18. Grimme FA, Goverde PA, Van Oostayen JA, et al. Covered stents for aortoiliac reconstruction of chronic occlusive lesions. J Cardiovasc Surg (Torino). 2012; 53: 279-289.
19. Humphries MD, Armstrong E, Laird J, et al. Outcomes of covered versus bare-metal balloon-expandable stents for aortoiliac occlusive disease. J Vasc Surg. 2014; 60: 337-343.
20. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012; 125: 130-139.
21. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol. 2015; 65: 999-1009.
22. Lepantalo M, Laurila K, Roth WD, et al. PTFE bypass or thrupass for superficial femoral artery occlusion? A randomised controlled trial. Eur J Vasc Endovasc Surg. 2009; 37: 578-584.
23. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005; 366: 1925-1934.
24. Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010; 51: 5S-17S.
25. Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg. 2010; 51: 18S-31S.
26. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008; 358: 689-699.
27. Faglia E, Clerici G, Airoldi F, et al. Revascularization by angioplasty of type D femoropopliteal and long infrapopliteal lesion in diabetic patients with critical limb ischemia: are TASC II recommendations suitable? A population-based cohort study. Int J Low Extrem Wounds. 2012; 11: 277-285.
28. Gargiulo M, Giovanetti F, Bianchini Massoni C, et al. Bypass to the ankle and foot in the era of endovascular therapy of tibial disease. Results and factors influencing the outcome. J Cardiovasc Surg (Torino.) 2014; 55: 367-374.
29. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006; 43: 742-751.
30. Lensvelt MM, Holewijn S, Fritschy WM, et al. SUrgical versus PERcutaneous Bypass: SUPERB-trial. Heparin-bonded endoluminal versus surgical femoro-popliteal bypass: study protocol for a randomized controlled trial. Trials. 2011; 12: 178.
31. Jones WS, Dolor RJ, Hasselblad V, et al. Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia: systematic review of revascularization in critical limb ischemia. Am Heart J. 2014; 167: 489-498 e487.
32. Twine CP, McLain AD,. Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst Rev. 2010:CD001487.
33. Pereira CE, Albers M, Romiti M, et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg. 2006; 44: 510-517.
34. Norgren L, Troeng T,. Personal communication on behalf of the Swedish Vascular Registry (SWEDVASC). 2010.
35. Geraghty PJ, Mewissen MW, Jaff MR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013; 58: 386-395 e384.
36. Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013; 24: 165-173.
37. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010; 3: 267-276.
38. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012; 19: 1-9.
39. Bown MJ, Bolia A, Sutton AJ,. Subintimal angioplasty: meta-analytical evidence of clinical utility. Eur J Vasc Endovasc Surg. 2009; 38: 323-337.
40. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006; 354: 1879-1888.
41. Brescia AA, Wickers BM, Correa JC, et al. Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg. 2015; 61: 1472-1478.
42. Das T, Mustapha J, Indes J, et al. Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremities: the CONFIRM series, a prospective multicenter registry. Catheter Cardiovasc Interv. 2014; 83: 115-122.
43. Dave RM, Patlola R, Kollmeyer K, et al. Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther. 2009; 16: 665-675.
44. Korabathina R, Mody KP, Yu J, et al. Orbital atherectomy for symptomatic lower extremity disease. Catheter Cardiovasc Interv. 2010; 76: 326-332.
45. Laird JR, Zeller T, Gray BH, et al. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther. 2006; 13: 1-11.
46. Zeller T, Krankenberg H, Steinkamp H, et al. One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial. J Endovasc Ther. 2009; 16: 653-662.
47. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006; 48: 1573-1578.
48. McKinsey JF, Zeller T, Rocha-Singh KJ, et al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014; 7: 923-933.
49. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013; 61: 2417-2427.
50. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014; 7: 10-19.
51. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015; 131: 495-502.
52. Antoniou GA, Chalmers N, Georgiadis GS, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg. 2013; 57: 242-253.
53. Hiatt WR,. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001; 344: 1608-1621.
54. Albers M, Romiti M, Brochado-Neto FC, et al. Meta-analysis of alternate autologous vein bypass grafts to infrapopliteal arteries. J Vasc Surg. 2005; 42: 449-455.
55. Albers M, Romiti M, Pereira CA, et al. Meta-analysis of allograft bypass grafting to infrapopliteal arteries. Eur J Vasc Endovasc Surg. 2004; 28: 462-472.
56. Dorweiler B, Neufang A, Schmiedt W, et al. Pedal arterial bypass for limb salvage in patients with diabetes mellitus. Eur J Vasc Endovasc Surg. 2002; 24: 309-313.
57. Kashyap VS, Ahn SS, Quinones-Baldrich WJ, et al. Infrapopliteal-lower extremity revascularization with prosthetic conduit: a 20-year experience. Vasc Endovascular Surg. 2002; 36: 255-262.
58. Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007; 46: 1180-1190.
59. Conte MS, Geraghty PJ, Bradbury AW, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009; 50: 1462-1473 e1461-1463.
60. Iida O, Nakamura M, Yamauchi Y, et al. Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia: OLIVE registry, a prospective, multicenter study in Japan with 12-month follow-up. Circ Cardiovasc Interv. 2013; 6: 68-76.
61. Iyer SS, Dorros G, Zaitoun R, et al. Retrograde recanalization of an occluded posterior tibial artery by using a posterior tibial cutdown: two case reports. Cathet Cardiovasc Diagn. 1990; 20: 251-253.
62. Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008; 47: 975-981.
63. Ansel GM, Sample NS, Botti IC Jr, et al. Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia. Catheter Cardiovasc Interv. 2004; 61: 1-4.
64. Das T, McNamara T, Gray B, et al. Cryoplasty therapy for limb salvage in patients with critical limb ischemia. J Endovasc Ther. 2007; 14: 753-762.
65. Zeller T, Rastan A, Schwarzwalder U, et al. Midterm results after atherectomy-assisted angioplasty of below-knee arteries with use of the Silverhawk device. J Vasc Interv Radiol. 2004; 15: 1391-1397.
66. White CJ,. Brave new world: value-based purchasing for peripheral vascular stents is coming to a hospital near you. Circulation. 2013; 127: 2475-2476.
67. Antoniou GA, Chalmers N, Kanesalingham K, et al. Meta-analysis of outcomes of endovascular treatment of infrapopliteal occlusive disease with drug-eluting stents. J Endovasc Ther. 2013; 20: 131-144.
68. Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012; 55: 390-398.
69. Fusaro M, Cassese S, Ndrepepa G, et al. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. JACC Cardiovasc Interv. 2013; 6: 1284-1293.
70. Katsanos K, Spiliopoulos S, Diamantopoulos A, et al. Systematic review of infrapopliteal drug-eluting stents: a meta-analysis of randomized controlled trials. Cardiovasc Intervent Radiol. 2013; 36: 645-658.
71. Rastan A, Brechtel K, Krankenberg H, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012; 60: 587-591.
72. Rastan A, Tepe G, Krankenberg H, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011; 32: 2274-2281.
73. Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012; 60: 2290-2295.
74. Yang X, Lu X, Ye K, et al. Systematic review and meta-analysis of balloon angioplasty versus primary stenting in the infrapopliteal disease. Vasc Endovascular Surg. 2014; 48: 18-26.
75. Siablis D, Kitrou PM, Spiliopoulos S, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014; 7: 1048-1056.
76. Rand T, Lammer J, Rabbia C, et al. Percutaneous transluminal angioplasty versus turbostatic carbon-coated stents in infrapopliteal arteries: InPeria II trial. Radiology. 2011; 261: 634-642.
77. Randon C, Jacobs B, De Ryck F, et al. Angioplasty or primary stenting for infrapopliteal lesions: results of a prospective randomized trial. Cardiovasc Intervent Radiol. 2010; 33: 260-269.
78. Feiring AJ, Krahn M, Nelson L, et al. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol. 2010; 55: 1580-1589.
79. Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009; 20: 1141-1150.
80. Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011; 58: 1105-1109.
81. Fanelli F, Cannavale A, Boatta E, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012; 19: 571-580.
82. Fanelli F, Cannavale A, Corona M, et al. The €DEBELLUM€-lower limb multilevel treatment with drug eluting balloon-randomized trial: 1-year results. J Cardiovasc Surg (Torino). 2014; 55: 207-216.
83. Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013; 128: 615-621.
84. Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014; 64: 1568-1576.
85. Farber A, Rosenfield K, Menard M,. The BEST-CLI trial: a multidisciplinary effort to assess which therapy is best for patients with critical limb ischemia. Tech Vasc Interv Radiol. 2014; 17: 221-224.
86. University of Birmingham Clinical Trials Unit. BASIL-2 trial. http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/portfolio-v/Basil-2/index.aspx. Accessed May 31, 2015.
87. Chang RW, Goodney PP, Baek JH, et al. Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive disease. J Vasc Surg. 2008; 48: 362-367.
88. Timaran CH, Stevens SL, Freeman MB, et al. Infrainguinal arterial reconstructions in patients with aortoiliac occlusive disease: the influence of iliac stenting. J Vasc Surg. 2001; 34: 971-978.
89. Creager MA, Goldstone J, Hirshfeld JW Jr, et al. ACC/ACP/SCAI/SVMB/SVS clinical competence statement on vascular medicine and catheter-based peripheral vascular interventions: a report of the American College of Cardiology/American Heart Association/American College of Physician Task Force on Clinical Competence (ACC/ACP/SCAI/SVMB/SVS Writing Committee to develop a clinical competence statement on peripheral vascular disease). J Am Coll Cardiol. 2004; 44: 941-957.
90. Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014; 59: 220-234 e221-222.